A new study, published in CNS Oncology estimates the survival benefit of adding tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Browsing: Disease Area > Brain and neurologic
A valuable cache of brain cancer biomedical data, termed REMBRANDT, has been made freely accessible to researchers worldwide.
Checkpoint inhibitors increase median survival to 12.4 months, and more than double percentage of patients who survive 4 years or longer.
Interim blinded survival data has been released from the Phase III clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma patients; early findings from the 11-year study involving more than 300 people worldwide demonstrates promising survival results
In this article from CNS Oncology discover two case reports of adenocarcinoma and breast carcinoma that metastasized into an intracranial meningioma.
Researchers have reported that children with incurable brain tumors could benefit from a potentially life-extending treatment, if genetic testing is utilized to personalize their therapy. This personalized treatment has previously only been used in adults.
In this interview discover some of the challenges in developing CAR-T therapies for solid tumors as well as major milestones in their development and where the field is heading.
In partnership with The Brain Tumour Charity, the awards hope to tackle six major themes in brain tumor research.
For the first time, Brazilian researchers have demonstrated the efficacy of the Zika virus in treating advanced-stage human CNS tumors in vivo.
In this review piece, we take a look at the most read cancer news stories from over the past year; highlights include drug approvals, genetic discoveries and immunotherapy advancements.